About Us
At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns.
To tackle these challenges, we are advancing an innovative pipeline of multi-modal small molecules all with novel mechanisms of action and a precision therapeutic approach. Our approach to developing therapeutics delivered locally to the site of inflammation is clinically and scientifically differentiated.
ADS051 is a first-in-class, oral, gut-restricted modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis that has completed a Phase 1b MAD clinical trial and will be moving into Phase 2 development later this year. Adiso is also developing ADS032, a first-in-class small molecule that acts as a dual inflammasome inhibitor (NLRP3 & NLRP1) and is in advanced pre-clinical development for the treatment of respiratory and dermal inflammation.
Team & Founders
Leadership Team
Discovery Team
Paul Ross, PhD
University College Cork, Ireland/APC Microbiome Institute
Colin Hill, PhD
University College Cork, Ireland/APC Microbiome Institute
Beth McCormick, PhD
The University of Massachusetts Chan Medical School
Our Development Pipeline
First-In-Class Small Molecule Modulator of Neutrophil Trafficking and Activation
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS051
Portfolio of First-In-Class Small Molecule Inhibitor of the NLRP3 and 1 Inflammasomes
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS032
Our Partnering Pipeline
Portfolio of Single Strain Live Biotherapeutic Products (SS-LBP)
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS024 CDI
ADS024 UC